Michaela Liedtke, Zhuoxin Sun, Mark R. Litzow, Ryan J Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Elad Sharon, Richard Little, Harry P. Erba, Richard M. Stone, Selina Luger, Charles G. Mullighan, Martin S. Tallman, Matthew J. Wieduwilt Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial , Blood: 2025
Pratz KW, Erba HP Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents , Am J Hematol: 2025
Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia , Blood Cancer J: 2025
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9: 2025,533-544
Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation , Transplantation and Cellular Therapy: 2025
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025
Pratz KW, Erba HP. Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents , Am J Hematol: 2025
Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Mark B Juckett, Yazan F. Madanat, Marcello Rotta, Keith W. Pratz, George Yaghmour, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amer M. Zeidan Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007 , Blood: 2024
Nikolai A. Podoltsev, Zhuoxin Sun, Mark R. Litzow, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard M. Stone, Charles G. Mullighan, Martin S. Tallman, Selina Luger, Ryan J Mattison Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial , Blood: 2024
Pratz KW Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1 , Br J Haematol: 2024